Patents by Inventor Dharmarao Thapi
Dharmarao Thapi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12180285Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind the Galactin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: GrantFiled: February 1, 2019Date of Patent: December 31, 2024Assignee: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi, Marina Stasenko
-
Publication number: 20240026009Abstract: Provided herein are compositions, methods, and uses involving antibodies that specifically bind the Galectin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: ApplicationFiled: December 7, 2021Publication date: January 25, 2024Inventors: David SPRIGGS, Dharmarao THAPI, Ivo C. LORENZ, Thomas E. WHITE
-
Patent number: 11834513Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: GrantFiled: July 28, 2020Date of Patent: December 5, 2023Assignee: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
-
Publication number: 20230026100Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: ApplicationFiled: July 14, 2021Publication date: January 26, 2023Inventors: David SPRIGGS, Alberto FERNANDEZ-TEJADA, Dharmarao THAPI
-
Publication number: 20220235143Abstract: Provided herein are compositions, methods, and uses involving anti-Mucin-16 (MUC16) agents that immunospecifically bind an epitope of Mucin-16 (MUC16). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer and diseases associated with positive MUC16 expression.Type: ApplicationFiled: May 7, 2020Publication date: July 28, 2022Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.Inventors: David SPRIGGS, Dharmarao THAPI, Su YAN, Cheng LIU
-
Publication number: 20210309758Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: ApplicationFiled: July 28, 2020Publication date: October 7, 2021Applicant: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
-
Patent number: 11066480Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: GrantFiled: March 16, 2016Date of Patent: July 20, 2021Assignee: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David Spriggs, Alberto Fernandez-Tejada, Dharmarao Thapi
-
Publication number: 20210032350Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind the Galactin-3 (LGALS3) carbohydrate binding domain (CBD). Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: ApplicationFiled: February 1, 2019Publication date: February 4, 2021Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: David SPRIGGS, Dharmarao THAPI, Marina STASENKO
-
Patent number: 10759869Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: GrantFiled: September 5, 2017Date of Patent: September 1, 2020Assignee: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
-
Publication number: 20180230231Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: ApplicationFiled: September 5, 2017Publication date: August 16, 2018Applicant: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
-
Publication number: 20180112008Abstract: Provided herein are compositions, methods, and uses involving antibodies that immunospecifically bind glycosylated forms of MUC16, a tethered mucin protein. Also provided herein are uses and methods for managing, treating, or preventing disorders, such as cancer.Type: ApplicationFiled: March 16, 2016Publication date: April 26, 2018Applicant: Memorial Sloan Kettering Cancer CenterInventors: David SPRIGGS, Alberto FERNANDEZ-TEJADA, Dharmarao THAPI
-
Patent number: 9790283Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: GrantFiled: September 10, 2015Date of Patent: October 17, 2017Assignee: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
-
Publication number: 20160168262Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: ApplicationFiled: September 10, 2015Publication date: June 16, 2016Applicant: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
-
Patent number: 9169328Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: GrantFiled: March 25, 2011Date of Patent: October 27, 2015Assignee: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
-
Publication number: 20130171152Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to a polypeptide, or antigenic portion thereof, wherein the polypeptide is selected from a) MUC16 ectodomain polypeptide, b) MUC16 cytoplasmic domain polypeptide, and c) MUC16 extracellular domain polypeptide that contains a cysteine loop polypeptide. The invention's antibodies and compositions containing them are useful in diagnostic and therapeutic applications for diseases in which MUC16 is overexpressed, such as cancer.Type: ApplicationFiled: March 25, 2011Publication date: July 4, 2013Applicant: Memorial Sloan Kettering Cancer CenterInventors: David Spriggs, Dharmarao Thapi
